Kalos Management’s Novo Nordisk NVO Stock Holding History

Kalos Management’s Portfolio NVO Stock Details NVO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-138,726	Closed	-$3.42M	–	209
2018 Q1	$3.42M	Buy	138,726 +1,936	+1%	+$50.8K	2.02%	12
2017 Q4	$3.67M	Sell	136,790 -1,652	-1%	-$42K	1.72%	8
2017 Q3	$3.33M	Buy	138,442 +4,160	+3%	+$94K	2.15%	7
2017 Q2	$2.88M	Buy	134,282 +4,990	+4%	+$101K	2.63%	7
2017 Q1	$2.22M	Buy	129,292 +16,672	+15%	+$290K	1.57%	25
2016 Q4	$2.02M	Buy	+112,620	New	+$2.04M	1.63%	20
2015 Q4	–	Hold	0	–	–	–	445

Other funds holding NVO

Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

State Farm Mutual Automobile Insurance Bloomington, Illinois $127B AUM 32.55% 1-Year Est. Return

Fayez Sarofim & Co Houston, Texas $39.1B AUM 15.14% 1-Year Est. Return

SGA

Sustainable Growth Advisers Stamford, Connecticut $10.6B AUM 2.6% 1-Year Est. Return

Kalos Management's NVO Position: Q2 2018 in Review

Kalos Management sold out of Novo Nordisk (NVO) in Q2 2018, closing a stake of 138,726 shares — an estimated $3.42M sold.

Kalos Management first reported a position in NVO in Q4 2016 and held it in 6 quarters. The position peaked at $3.67M in Q4 2017. 537 funds tracked by Wall St. Rank hold NVO as of Q2 2018.

Kalos Management reported no remaining Novo Nordisk position as of Q2 2018 after selling out during the quarter.
Kalos Management sold 138,726 Novo Nordisk shares in Q2 2018, an estimated $3.42M.
Kalos Management first reported a position in Novo Nordisk in Q4 2016 and held it in 6 quarters.
Kalos Management's Novo Nordisk position peaked at $3.67M in Q4 2017.
537 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2018.

Based on Kalos Management's 13F filing for Q2 2018, filed 14 Aug 2018.